AstraZeneca has announced the results from the EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial that showed cardiovascular safety with Bydureon (exenatide extended-release) in patients with type 2 diabetes at a wide range of CV risk.

The drug was found not to increase the incidence of major adverse cardiovascular events (MACE), a composite endpoint of CV death, non-fatal heart attack or non-fatal stroke, compared to placebo. There were also fewer CV events observed in the exenatide arm of the trial.